Share
Save
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
The Phase 1 safety study of VOY-101 comprises of escalating dose Cohorts, followed by a Phase 2a.
Study details:
This is a prospective, open-label, multi-center Phase 1/2a study to evaluate the safety of a single, unilateral intravitreal (IVT) injection of escalating dose levels of VOY-101 therapy in subjects with advanced non-neovascular age-related macular degeneration (AMD).
Eligibility criteria
Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.
Inclusion criteria
Exclusion criteria
Eligibility
Age eligible for study : 50 and older
Healthy volunteers accepted : No
Gender eligible for study: All
Things to know
Study dates
Study start: 2023-06-21
Primary completion: 2026-10-01
Study completion finish: 2027-10-01
Study type
TREATMENT
Phase
PHASE1
PHASE2
Trial ID
NCT06087458
Intervention or treatment
BIOLOGICAL: VOY-101
Conditions
- • Age-Related Macular Degeneration
Find a site
Closest Location:
Sydney Retina Clinic and Day Surgery
Research sites nearby
Select from list below to view details:
Sydney Retina Clinic and Day Surgery
Sydney, New South Wales, Australia
Cerulea Clinical Trials
East Melbourne, Victoria, Australia
Cabrini Research
Melbourne, Victoria, Australia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Participant Group/Arm | Intervention/Treatment |
---|---|
EXPERIMENTAL: Experimental: Low
| BIOLOGICAL: VOY-101
|
EXPERIMENTAL: Experimental: Medium
| BIOLOGICAL: VOY-101
|
EXPERIMENTAL: Experimental: High
| BIOLOGICAL: VOY-101
|
EXPERIMENTAL: Experimental: Higher
| BIOLOGICAL: VOY-101
|
What is the study measuring?
Primary outcome
Primary Outcome Measure | Primary Outcome Description | Primary Outcome Time Frame |
---|---|---|
Safety and Tolerability as measured by frequency of ocular and systemic adverse events (AEs) (serious [SAEs] and treatment-emergent non-serious adverse events [TEAEs]) | Not Specified | 24 months |
Secondary outcome
Frequently Asked Questions
Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol
No questions submitted. Be the first to ask a question!